Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976) intends to acquire 6.13% stake in HeraMED Limited (ASX:HMD) from Hua Li Pharmaceutical Group Co.,Ltd. for AUD 2.1 million on November 12, 2021. The board of Jianmin Pharmaceutical Group Co.,Ltd. approved the deal. Jianmin Pharmaceutical Group Co.,Ltd. will fund the acquisition with existing funds not exceeding AUD 2.1 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.016 AUD | +6.67% | -8.57% | -33.33% |
May. 13 | Transcript : HeraMED Limited - Special Call | |
May. 08 | HeraMED Obtains ASIC Approval for Extension to Hold 2024 Meeting | MT |
1st Jan change | Capi. | |
---|---|---|
-33.33% | 3.54M | |
-7.79% | 3.13B | |
+4.27% | 188M | |
-14.72% | 84.35M | |
+13.04% | 51M | |
-52.50% | 50.99M |
- Stock Market
- Equities
- HMD Stock
- News HeraMED Limited
- Jianmin Pharmaceutical Group Co.,Ltd. intends to acquire 6.13% stake in HeraMED Limited from Hua Li Pharmaceutical Group Co.,Ltd. for AUD 2.1 million.